Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk

Researchers have just published a study in Nature Genetics that marks a significant shift in how we track disease risks. By using nanoparticle-enriched mass spectrometry to analyze blood samples from more than 1,400 participants of British Bangladeshi and Pakistani ancestry, the team identified thousands of protein groups that were previously undetected by standard affinity-based methods. This cohort is historically underrepresented in genetic research, yet faces higher rates of cardiometabolic conditions, making these findings critical for future medical intervention.

The study reveals that differences in how blood proteomic platforms perform are largely due to technical factors rather than biology. By mapping the proteome with this high level of precision, the researchers uncovered 1,217 significant associations between genetic loci and protein levels. Over half of these associations were previously unreported. One key finding highlights a common variant in the IGLV3-21 gene that is linked to a decreased risk of Graves' disease. This insight suggests that targeting specific B-cell populations could be a viable therapeutic strategy for autoimmune conditions.

This work highlights how integrating diverse genetic backgrounds and advanced mass spectrometry leads to a clearer understanding of human disease mechanisms. By linking rare and common genetic variants to specific plasma protein levels, the team identified 690 connections between proteins and disease risk. This approach paves the way for drug target selection and repurposing. The research underscores the necessity of broad proteome coverage to move beyond correlation toward clear biological causality.